




RealRate

PHARMACEUTICAL 2025

Talpheria INC
Rank 131 of 225

AcelRx
Pharmaceuticals, Inc.



The relative strengths and weaknesses of Talpheria INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Talpheria INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Talpheria INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 43% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	9,417
Cost of Goods Sold	0
Intangible Assets	8,819
Liabilities, Current	2,647
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	7,588
Other Net Income	2,248
Other Revenues	0
Property and Equipment	0
Research and Development	6,718
Selling, General and Administrative Expense	8,534

Output Variable	Value in 1000 USD
Assets	18,236
Liabilities	10,235
Expenses	15,252
Revenues	0
Stockholders Equity	8,001
Net Income	-13,004
Comprehensive Net Income	-13,004
BaseVar	22,986
ECR before LimitedLiability	31%
Economic Capital Ratio	171%